WO 2010/142017 Al
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Correlation of Cytokine Level with the Severity of Severe Fever With
Liu et al. Virology Journal (2017) 14:6 DOI 10.1186/s12985-016-0677-1 RESEARCH Open Access Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome Miao-Miao Liu1, Xiao-Ying Lei1, Hao Yu2, Jian-zhi Zhang3 and Xue-jie Yu1,4* Abstract Background: Severe fever with thrombocytopenia syndrome (SFTS) was an emerging hemorrhagic fever that was caused by a tick-borne bunyavirus, SFTSV. Although SFTSV nonstructural protein can inhibit type I interferon (IFN-I) production Ex Vivo and IFN-I played key role in resistance SFTSV infection in animal model, the role of IFN-I in patients is not investigated. Methods: We have assayed the concentration of IFN-α, a subtype of IFN-I as well as other cytokines in the sera of SFTS patients and the healthy population with CBA (Cytometric bead array) assay. Results: The results showed that IFN-α, tumor necrosis factor (TNF-α), granulocyte colony-stimulating factor (G-CSF), interferon-γ (IFN-γ), macrophage inflammatory protein (MIP-1α), interleukin-6 (IL-6), IL-10, interferon-inducible protein (IP-10), monocyte chemoattractant protein (MCP-1) were significantly higher in SFTS patients than in healthy persons (p < 0.05); the concentrations of IFN-α, IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10 were significant higher in severe SFTS patients than in mild SFTS patients (p < 0.05). Conclusion: The concentration of IFN-α as well as other cytokines (IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10) is correlated with the severity of SFTS, suggesting that type I interferon may not be significant in resistance SFTSV infection in humans and it may play an import role in cytokine storm. -
Innate Immunity Evasion by Dengue Virus
Viruses2012, 4, 397-413; doi:10.3390/v4030397 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Innate Immunity Evasion by Dengue Virus Juliet Morrison, Sebastian Aguirre and Ana Fernandez-Sesma * Department of Microbiology and the Global Health and Emerging Pathogens Institute (GHEPI), Mount Sinai School of Medicine, New York, NY 10029-6574, USA; E-Mails: [email protected] (J.M.); [email protected] (S.A.) * Author to whom correspondence should be addressed: E-Mail: [email protected]; Tel.: +1-212-241-5182; Fax: +1-212-534-1684. Received: 30 January 2012; in revised version: 14 February 2012 / Accepted: 7 March 2012 / Published: 15 March 2012 Abstract: For viruses to productively infect their hosts, they must evade or inhibit important elements of the innate immune system, namely the type I interferon (IFN) response, which negatively influences the subsequent development of antigen-specific adaptive immunity against those viruses. Dengue virus (DENV) can inhibit both type I IFN production and signaling in susceptible human cells, including dendritic cells (DCs). The NS2B3 protease complex of DENV functions as an antagonist of type I IFN production, and its proteolytic activity is necessary for this function. DENV also encodes proteins that antagonize type I IFN signaling, including NS2A, NS4A, NS4B and NS5 by targeting different components of this signaling pathway, such as STATs. Importantly, the ability of the NS5 protein to bind and degrade STAT2 contributes to the limited host tropism of DENV to humans and non-human primates. In this review, we will evaluate the contribution of innate immunity evasion by DENV to the pathogenesis and host tropism of this virus. -
Accepted Manuscript
Lawrence Berkeley National Laboratory Recent Work Title CVID enteropathy is characterized by exceeding low mucosal IgA levels and interferon- driven inflammation possibly related to the presence of a pathobiont. Permalink https://escholarship.org/uc/item/7qv434pj Authors Shulzhenko, Natalia Dong, Xiaoxi Vyshenska, Dariia et al. Publication Date 2018-12-01 DOI 10.1016/j.clim.2018.09.008 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Accepted Manuscript CVID enteropathy is characterized by exceeding low mucosal iga levels and interferon-driven inflammation possibly related to the presence of a pathobiont Natalia Shulzhenko, Xiaoxi Dong, Dariia Vyshenska, Renee L. Greer, Manoj Gurung, Stephany Vasquez-Perez, Ekaterina Peremyslova, Stanislav Sosnovtsev, Martha Quezado, Michael Yao, Kim Montgomery-Recht, Warren Strober, Ivan J. Fuss, Andrey Morgun PII: S1521-6616(18)30294-8 DOI: doi:10.1016/j.clim.2018.09.008 Reference: YCLIM 8102 To appear in: Clinical Immunology Received date: 25 April 2018 Revised date: 2 August 2018 Accepted date: 16 September 2018 Please cite this article as: Natalia Shulzhenko, Xiaoxi Dong, Dariia Vyshenska, Renee L. Greer, Manoj Gurung, Stephany Vasquez-Perez, Ekaterina Peremyslova, Stanislav Sosnovtsev, Martha Quezado, Michael Yao, Kim Montgomery-Recht, Warren Strober, Ivan J. Fuss, Andrey Morgun , CVID enteropathy is characterized by exceeding low mucosal iga levels and interferon-driven inflammation possibly related to the presence of a pathobiont. Yclim (2018), doi:10.1016/j.clim.2018.09.008 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. -
(12) Patent Application Publication (10) Pub. No.: US 2016/0367695A1 Wilson Et Al
US 20160367695A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0367695A1 Wilson et al. (43) Pub. Date: Dec. 22, 2016 (54) POLYPEPTIDE CONSTRUCTS AND USES (30) Foreign Application Priority Data THEREOF Oct. 28, 2011 (AU) ................................ 2011 9045O2 (71) Applicant: Teva Pharmaceuticals Australia Pty Ltd, Macquarie Park (AU) Publication Classification (72) Inventors: David S. Wilson, Freemont, CA (US); Sarah L. Pogue, Freemont, CA (US); (51) Int. Cl. Glen E. Mikesell, Pacifica, CA (US); A6II 47/48 (2006.01) Tetsuya Taura, Palo Alto, CA (US); C07K 6/28 (2006.01) Wouter Korver, Mountain View, CA (52) U.S. Cl. (US); Anthony G. Doyle, Drummoyne CPC ..... A61K 47/48269 (2013.01); C07K 16/2896 (AU); Adam Clarke, Five Dock (AU); (2013.01); C07K 231 7/565 (2013.01); C07K Matthew Pollard, Dural (AU): 2317/55 (2013.01); C07K 2317/92 (2013.01) Stephen Tran, Strathfield South (AU); Jack Tzu Chiao Lin, Redwood City, (57) ABSTRACT CA (US) (21) Appl. No.: 15/194,926 The present invention provides a polypeptide construct (22) Filed: Jun. 28, 2016 comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which Related U.S. Application Data binds to a cell Surface-associated antigen, wherein the ligand (63) Continuation of application No. 14/262,841, filed on comprises at least one amino acid Substitution or deletion Apr. 28, 2014, which is a continuation of application which reduces its potency on cells lacking expression of said No. PCT/AU2012/001323, filed on Oct. 29, 2012. antigen. Patent Application Publication Dec. -
Rousettus Aegyptiacus Amy J
Schuh et al. Parasites & Vectors (2016) 9:128 DOI 10.1186/s13071-016-1390-z SHORT REPORT Open Access No evidence for the involvement of the argasid tick Ornithodoros faini in the enzootic maintenance of marburgvirus within Egyptian rousette bats Rousettus aegyptiacus Amy J. Schuh1, Brian R. Amman1, Dmitry A. Apanaskevich2, Tara K. Sealy1, Stuart T. Nichol1 and Jonathan S. Towner1* Abstract Background: The cave-dwelling Egyptian rousette bat (ERB; Rousettus aegyptiacus) was recently identified as a natural reservoir host of marburgviruses. However, the mechanisms of transmission for the enzootic maintenance of marburgviruses within ERBs are unclear. Previous ecological investigations of large ERB colonies inhabiting Python Cave and Kitaka Mine, Uganda revealed that argasid ticks (Ornithodoros faini) are hematophagous ectoparasites of ERBs. Yet, their potential role as transmission vectors for marburgvirus has not been sufficiently assessed. Findings: In the present study, 3,125 O. faini were collected during April 2013 from the rock crevices of Python Cave, Uganda. None of the ticks tested positive for marburgvirus-specific RNA by Q-RT-PCR. The probability of failure to detect marburgvirus at a conservative prevalence of 0.1 % was 0.05. Conclusions: The absence of marburgvirus RNA in O. faini suggests they do not play a significant role in the transmission and enzootic maintenance of marburgvirus within their natural reservoir host. Keywords: Filovirus, Marburgvirus, Marburg virus, Tick, Argasid, Ornithodoros, Egyptian rousette bat, Rousettus aegyptiacus, Transmission, Maintenance Findings IgG antibodies [3, 4] and the isolation of infectious mar- Introduction burgvirus [1–3, 5] from ERBs inhabiting caves associated The genus Marburgvirus (Filoviridae), includes a single with recent human outbreaks. -
The Molecular Characterization and the Generation of a Reverse Genetics System for Kyasanur Forest Disease Virus by Bradley
The Molecular Characterization and the Generation of a Reverse Genetics System for Kyasanur Forest Disease Virus by Bradley William Michael Cook A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of Master of Science Department of Microbiology University of Manitoba Winnipeg, Manitoba, Canada Copyright © 2010 by Bradley William Michael Cook 1 List of Abbreviations: AHFV - Alkhurma Hemorrhagic Fever Virus Amp – ampicillin APOIV - Apoi Virus ATP – adenosine tri-phosphate BAC – bacterial artificial chromosome BHK – Baby Hamster Kidney BSA – bovine serum albumin C1 – C-terminus fragment 1 C2 – C-terminus fragment 2 C - Capsid protein cDNA – comlementary Deoxyribonucleic acid CL – Containment Level CO2 – carbon dioxide cHP - capsid hairpin CNS - Central Nervous System CPE – cytopathic effect CS - complementary sequences DENV1-4 - Dengue Virus DIC - Disseminated Intravascular Coagulation (DIC) DNA – Deoxyribonucleic acid DTV - Deer Tick Virus 2 E - Envelope protein EDTA - ethylenediaminetetraacetic acid EM - Electron Microscopy EMCV – Encephalomyocarditis Virus ER - endoplasmic reticulum FBS – fetal bovine serum FP - fusion peptide GGEV - Greek Goat Encephalitis Virus GGYV - Gadgets Gully Virus GMP - Guanosine mono-phosphate GTP - Guanosine tri-phosphate HBV- Hepatitis B Virus HDV – Hepatitis Delta Virus HIV - Human Immunodeficiency Virus IFN – interferon IRES – internal ribosome entry sequence JEV - Japanese Encephalitis Virus KADV - Kadam Virus kDa - -
Risk Groups: Viruses (C) 1988, American Biological Safety Association
Rev.: 1.0 Risk Groups: Viruses (c) 1988, American Biological Safety Association BL RG RG RG RG RG LCDC-96 Belgium-97 ID Name Viral group Comments BMBL-93 CDC NIH rDNA-97 EU-96 Australia-95 HP AP (Canada) Annex VIII Flaviviridae/ Flavivirus (Grp 2 Absettarov, TBE 4 4 4 implied 3 3 4 + B Arbovirus) Acute haemorrhagic taxonomy 2, Enterovirus 3 conjunctivitis virus Picornaviridae 2 + different 70 (AHC) Adenovirus 4 Adenoviridae 2 2 (incl animal) 2 2 + (human,all types) 5 Aino X-Arboviruses 6 Akabane X-Arboviruses 7 Alastrim Poxviridae Restricted 4 4, Foot-and- 8 Aphthovirus Picornaviridae 2 mouth disease + viruses 9 Araguari X-Arboviruses (feces of children 10 Astroviridae Astroviridae 2 2 + + and lambs) Avian leukosis virus 11 Viral vector/Animal retrovirus 1 3 (wild strain) + (ALV) 3, (Rous 12 Avian sarcoma virus Viral vector/Animal retrovirus 1 sarcoma virus, + RSV wild strain) 13 Baculovirus Viral vector/Animal virus 1 + Togaviridae/ Alphavirus (Grp 14 Barmah Forest 2 A Arbovirus) 15 Batama X-Arboviruses 16 Batken X-Arboviruses Togaviridae/ Alphavirus (Grp 17 Bebaru virus 2 2 2 2 + A Arbovirus) 18 Bhanja X-Arboviruses 19 Bimbo X-Arboviruses Blood-borne hepatitis 20 viruses not yet Unclassified viruses 2 implied 2 implied 3 (**)D 3 + identified 21 Bluetongue X-Arboviruses 22 Bobaya X-Arboviruses 23 Bobia X-Arboviruses Bovine 24 immunodeficiency Viral vector/Animal retrovirus 3 (wild strain) + virus (BIV) 3, Bovine Bovine leukemia 25 Viral vector/Animal retrovirus 1 lymphosarcoma + virus (BLV) virus wild strain Bovine papilloma Papovavirus/ -
Table of Contents
Table of Contents Table of Contents Welcome Note of the German Research Platform for Zoonoses ........................................................ 2 Welcome Note of the Federal Government ...................................................................................... 3 Program Zoonoses 2019 - International Symposium on Zoonoses Research ...................................... 5 General information ...................................................................................................................... 14 Floor Plan .................................................................................................................................... 18 About the German Research Platform for Zoonoses ........................................................................ 19 Oral Presentations ........................................................................................................................ 20 Plenary Session I: Keynotes .......................................................................................................... 21 Session 1: Innate and Adaptive Immune Response......................................................................... 24 Session 2: Public Health ................................................................................................................ 31 Session 3: New and Re-Emerging Zoonotic Diseases ...................................................................... 38 Session 4: Diagnostics and NGS ................................................................................................... -
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0331966 A1 STOVER Et Al
US 20200331966A1 IN ( 19 ) United States ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0331966 A1 STOVER et al . ( 43 ) Pub . Date : Oct. 22 , 2020 ( 54 ) FUSION PROTEIN COMPOSITION ( S ) Related U.S. Application Data COMPRISING MASKED TYPE I INTERFERONS ( IFNA AND IFNB ) FOR USE ( 60 ) Provisional application No. 62 / 920,140 , filed on Apr. IN THE TREATMENT OF CANCER AND 15 , 2019 . METHODS THEREOF Publication Classification ( 71 ) Applicant: Qwixel Therapeutics, Los Angeles, CA ( 51 ) Int. Ci . ( US ) CO7K 7/08 ( 2006.01 ) A61K 47/65 ( 2006.01 ) ( 72 ) Inventors : David STOVER , Encino, CA (US ) ; A61P 35/00 ( 2006.01 ) Sherie MORRISON , Los Angeles, CA ( 52 ) U.S. CI . ( US ) ; Alex VASUTHASAWAT , Los CPC CO7K 7/08 ( 2013.01 ) ; A61K 38/00 Angeles , CA ( US ) ; Kham TRINH , ( 2013.01 ) ; A61P 35/00 ( 2018.01 ) ; A61K 47/65 Porter Ranch , CA ( US ) ; George ( 2017.08 ) AYOUB , Los Angeles, CA ( US ) ( 57 ) ABSTRACT Fusion Protein compositions comprising masked IFNs and ( 73 ) Assignee : Qwixel Therapeutics, Los Angeles, CA methods of making masked IFNs are disclosed herein . ( US ) Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as ( 21 ) Appl. No .: 16 /849,889 a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease . ( 22 ) Filed : Apr. 15 , 2020 Specification includes a Sequence Listing . Matripase ST 14 Cleaves an IFN Mask from the Heavy Chain of an anti CD138 Fusion Ab . 1 2 3 1. ant - CD138 / Na 2. anti - C0138 IFNa mask 3. anti - C0138 FNa mask w / MST14 Patent Application Publication Oct. -
United States Patent (10) Patent No.: US 9,464,124 B2 Bancel Et Al
USOO9464124B2 (12) United States Patent (10) Patent No.: US 9,464,124 B2 Bancel et al. (45) Date of Patent: Oct. 11, 2016 (54) ENGINEERED NUCLEIC ACIDS AND 4,500,707 A 2f1985 Caruthers et al. METHODS OF USE THEREOF 4,579,849 A 4, 1986 MacCoSS et al. 4,588,585 A 5/1986 Mark et al. 4,668,777 A 5, 1987 Caruthers et al. (71) Applicant: Moderna Therapeutics, Inc., 4,737.462 A 4, 1988 Mark et al. Cambridge, MA (US) 4,816,567 A 3/1989 Cabilly et al. 4,879, 111 A 11/1989 Chong (72) Inventors: Stephane Bancel, Cambridge, MA 4,957,735 A 9/1990 Huang (US); Jason P. Schrum, Philadelphia, 4.959,314 A 9, 1990 Mark et al. 4,973,679 A 11/1990 Caruthers et al. PA (US); Alexander Aristarkhov, 5.012.818 A 5/1991 Joishy Chestnut Hill, MA (US) 5,017,691 A 5/1991 Lee et al. 5,021,335 A 6, 1991 Tecott et al. (73) Assignee: Moderna Therapeutics, Inc., 5,036,006 A 7, 1991 Sanford et al. Cambridge, MA (US) 9. A 228 at al. J. J. W. OS a 5,130,238 A 7, 1992 Malek et al. (*) Notice: Subject to any disclaimer, the term of this 5,132,418 A 7, 1992 °N, al. patent is extended or adjusted under 35 5,153,319 A 10, 1992 Caruthers et al. U.S.C. 154(b) by 0 days. 5,168,038 A 12/1992 Tecott et al. 5,169,766 A 12/1992 Schuster et al. -
By Virus Screening in DNA Samples
Figure S1. Research of endogeneous viral element (EVE) by virus screening in DNA samples: comparison of Cp values results obtained when detecting the viruses in DNA samples (Light gray) versus Cp values results obtained in the corresponding RNA samples (Dark gray). *: significative difference with p-value < 0.05 (T-test). The S segment of the LTV were found in only one DNA sample and in the corresponding RNA sample. KTV has been detected in one DNA sample but not in the corresponding RNA sample. Figure S2. Luciferase activity (in LU/mL) distribution of measures after LIPS performed in tick/cattle interface for the screening of antibodies specific to Lihan tick virus (LTV), Karukera tick virus (KTV) and Wuhan tick virus 2 (WhTV2). Positivity threshold is indicated for each antigen construct with a dashed line. Table S1. List of tick-borne viruses targeted by the microfluidic PCR system (Gondard et al., 2018) Family Genus Species Asfarviridae Asfivirus African swine fever virus (ASFV) Orthomyxoviridae Thogotovirus Thogoto virus (THOV) Dhori virus (DHOV) Reoviridae Orbivirus Kemerovo virus (KEMV) Coltivirus Colorado tick fever virus (CTFV) Eyach virus (EYAV) Bunyaviridae Nairovirus Crimean-Congo Hemorrhagic fever virus (CCHF) Dugbe virus (DUGV) Nairobi sheep disease virus (NSDV) Phlebovirus Uukuniemi virus (UUKV) Orthobunyavirus Schmallenberg (SBV) Flaviviridae Flavivirus Tick-borne encephalitis virus European subtype (TBE) Tick-borne encephalitis virus Far-Eastern subtype (TBE) Tick-borne encephalitis virus Siberian subtype (TBE) Louping ill virus (LIV) Langat virus (LGTV) Deer tick virus (DTV) Powassan virus (POWV) West Nile virus (WN) Meaban virus (MEAV) Omsk Hemorrhagic fever virus (OHFV) Kyasanur forest disease virus (KFDV). -
Macrophage Activation: Dissociation of Cytotoxic Activity from Ia-A Antigen Expression (Fibroblast Interferon/Immune Interferon/Lymphokine) ELLIOTT J
Proc. Nati. Acad. Sci. USA Vol. 80, pp. 2031-2035, April 1983 Immunology Macrophage activation: Dissociation of cytotoxic activity from Ia-A antigen expression (fibroblast interferon/immune interferon/lymphokine) ELLIOTT J. BLUMENTHAL, WALDEN K. ROBERTS, ADRIANA VASIL, AND DAVID W. TALMAGE Department of Microbiology and Immunology, University of Colorado Health Sciences Center, Denver, Colorado 80262 Contributed by David W. Talmage, December 20, 1982 ABSTRACT Peritoneal macrophages were obtained from MATERIALS AND METHODS DBA/2 mice that were untreated or after the injection of bacillus Cainette-Guerin (BCG), thioglycollate broth, proteose-peptone Mice. Our source of peritoneal macrophages was DBA/2 broth, or gamma-irradiated P-815 tumor cells. These macro- mice that were less than 3 months old (The Jackson Labo- phages were "activated" to become cytotoxic for a fibroblast cell ratory). line (L 929) by the addition of lymphokines (LKs), lipopolysac- Elicitation of Peritoneal Macrophages. Peritoneal exudate charide (LPS), or fibroblast interferon (IFN-.3), and the expres- cells were collected by lavage with 5 ml of sterile Eagle min- sion of I region-associated antigens (Ia-Ad) on the macrophages imal essential medium. Resident cells were removed from un- was examined both before and after activation. Thioglycollate- treated mice. Cells were also obtained (a) 3-4 days after the elicited macrophages became Ia-A' when activated by LKs, but injection of 1 ml of 3% thioglycollate in broth that had been they remained la-A- when activated by LPS or IFN-f3. Resident "aged" for at least 6 months at 40C or (b) 3 days after intra- macrophages and proteose-peptone-elicited macrophages re- peritoneal injection of 1 ml of 1% proteose-peptone broth.